EGAd (weeks) | Time to novel infection (days) | Time to recrudescent infection (days) | Intercalated P. vivax | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Anti-malarial (action, years)a | Nb | Median [range] | N | Median [range] | N | Median [range] | % >28 days | % >42 days | % >63 days | % (N)c |
Quinine monotherapy (short, 1994–2006) | 476 | 17 [3–36] | 173 | 47 [7–216] | 303 | 21 [7–126] | 25.4 (77/303) | 10.6 (32/303) | 5.0 (15/303) | 33.0 (58) |
Quinine + clindamycin (short, 1998–2009) | 29 | 10 [4–24] | 22 | 84 [28–201] | 7 | 50 [21–122] | 57.1 (4/7) | 57.1 (4/7) | 42.9 (3/7) | 7.4 (13) |
Artesunate monotherapy (short, 1995–2008) | 151 | 21 [4–37] | 102 | 54 [8–182] | 49 | 22 [11–99] | 30.6 (15/49) | 12.2 (6/49) | 4.1 (2/49) | 21.6 (38) |
Artesunate + Clindamycin (short, 1998–2009) | 143 | 23e [1–39] | 121 | 49 [21–158] | 22 | 28 [12–70] | 45.5 (10/22) | 27.3 (6/22) | 9.1 (2/22) | 26.1 (46) |
Artemether + lumefantrine (medium, 2004–2006) | 43 | 23 [13–36] | 24 | 36 [15–140] | 19 | 23 [14–63] | 31.6 (6/19) | 26.3 (5/19) | 0.0 (0/19) | 6.3 (11) |
Artesunate + Atovaquone + proguanil (medium, 1999–2005) | 11 | 23 [18–32] | 8 | 67 [44–101] | 3 | 49 [35–120] | 100.0 (3/3) | 66.7 (2/3) | 33.3 (1/3) | 1.7 (3) |
Mefloquine monotherapy (long, 1994–1997) | 22 | 26 [12–38] | 4 | 25 [9–44] | 18 | 22 [7–123] | 27.8 (5/18) | 5.6 (1/18) | 5.6 (1/18) | 0 (0) |
DHAf + Piperaquine (long, 2006–2008) | 29 | 20 [8–34] | 23 | 63 [35–180] | 6 | 33 [21–49] | 66.7 (4/6) | 16.7 (1/6) | 0.0 (0/6) | 4.0 (7) |
Artesunate + Mefloquine (long, 1995–2008) | 5 | 28 [−0.4-39] | 4 | 35 [20–43] | 1 | 21 [−] | 0.0 (0/1) | 0.0 (0/1) | 0.0 (0/1) | 0 (0) |